Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.
December 05 2017 - 8:00AM
Business Wire
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to
discuss fiscal 2018 first quarter results Friday, December 8, 2017,
at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609.
International callers can dial 1-973-321-1024. When prompted, use
PIN number 3678737. Dial in approximately ten minutes prior to the
scheduled teleconference time. A rebroadcast of the call will be
available starting approximately two hours after the conference
call ends, through 11:30 PM (E.T.) Friday, December 22, 2017. The
replay of the conference call can be accessed by dialing
1-855-859-2056 (International callers can dial 1-404-537-3406) and,
when prompted, use the same PIN number 3678737.
Enzo’s conference call can also be accessed live over the
Internet at: https://tinyurl.com/yd96bbmv
To listen to the live call, individuals should go to the web
site at least 15 minutes early to register, download and install
any necessary audio software. Any pop up blocker installed on your
PC should be disabled while accessing the webcast.
A press release announcing first quarter 2018 results will be
distributed, Thursday, December 7, 2017 after the market
closes.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2017. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171205005473/en/
For: Enzo Biochem, Inc.Steve Anreder,
212-532-3232steven.anreder@anreder.comorCEOcast, Inc.Michael Wachs,
212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024